Boston's biotech crown is slipping. San Francisco is reaching for it.

The first check came with a free lab. Wong. They passed. He moved Integrated Biosciences to San Carlos, Calif., in 2022, and Sand Hill Road's risk-tolerant capital came with desk space attached. The company has since grown to more than a dozen scientists in over 5,000 square feet of office and lab space, working on AI-discovered molecules meant to slow aging. "To start a big company in Boston, you want at least half your head to be gray", Wong told STAT. "There's some crazy experiments that we're currently running at Integrated that I probably would not have thought about when I was in Boston."

Wong is one founder. The data point behind him is the question of the week. In a Readout newsletter dated Aug. 7, STAT flagged a report from MassBio, the Massachusetts biotech trade group, showing that the state's share of US biopharma funding slipped roughly two percentage points year over year, with California's share growing by about the same. The Boston Globe's Emma Platoff reported the same number on Aug. 5 and quoted MassBio CEO Kendalle Burlin O'Connell framing Wong as the kind of founder Massachusetts is failing to retain. O'Connell also pointed to record-high outmigration of 26- to 34-year-olds from the state.

That is the trade group's reading, and MassBio has a stake in flagging Massachusetts weakness. The 2-point move is also a single-year data point, not a long trend. But it lands on top of a list of pressures the Globe laid out: layoffs, vacant lab space, slower post-pandemic recovery than peer states, a venture capital downturn that has not lifted, and renewed competition with Chinese biotechs operating under a different cost base.

The current generation looks more like an AI lab. Integrated Biosciences, like a growing slice of new biotech, builds its pipeline by screening libraries of millions of small molecules with neural networks before any animal work begins. That is a heavier compute bill, a faster iteration loop, and a different buyer: investors who have lived through software cycles and want the same iteration speed in biology. The Boston investors Wong pitched in 2021 had spent careers underwriting a different kind of bet.

This week's other news from the same Readout shows what AI-era biotech capital looks like in practice. The FDA granted accelerated approval to Replimune's RP1, a melanoma therapy branded Tudriqev that the agency had twice rejected, at a list price of $450,000. A Stanford team published a paper in Neuron arguing that tau, the protein that clumps in Alzheimer's brains, may damage neurons through a reverse-electron-transport mechanism that rewires mitochondria. Neither item is the lead, but together they describe the operating environment. Regulators are reopening risky single-arm oncology trials. Capital is chasing science that needs compute clusters, bench scientists, and FDA review at the same time. A biotech capital in 2026 has to provide all three, plus a place to test them.

The open question is what Massachusetts does about it. O'Connell is calling on the state to lean into the science it already has, and Wong's case shows the limits of that pitch when the founder is in his thirties and the experiment sounds implausible. The MassBio report itself places California's share gain in the same 2-point band as Massachusetts's loss, and Boston still hosts the densest cluster of biopharma headquarters, contract research organizations, and academic medical centers in the country. The Readout frames it as a drift, not a verdict.

The watch items are narrow. The next MassBio report will show whether the 2-point gap widens into a trend or closes as the venture market normalizes. Boston's landlords and lab developers will show whether new space is being built for AI-bio tenants or for the patient-capital version of the last decade. And the FDA's willingness to revisit single-arm oncology submissions, signaled by the Replimune decision, will show how much of the AI-bio bet the regulator is willing to underwrite. None of those numbers will settle the question STAT asked. They will tell readers whether the next twelve months of biotech capital stories are about a slow drift or a step function.